Clinical Scorecard: Analysis of Muscle Injury Mechanisms in Duchenne Muscular Dystrophy: Insights from Transcriptomics and Inflammatory Imbalance in the Muscle Microenvironment

At a Glance

Key Highlights

• PTPRC identified as a candidate biomarker for DMD-related fibrosis
• Increased immune infiltration by M2 macrophages and Tregs in PTPRC_High patients
• ECM activation scores correlate with DMD status and diagnostic efficacy
• Silencing PTPRC enhances myogenic differentiation and reduces fibrosis in myoblasts
• Persistent inflammation and ECM deposition accelerate muscle injury in DMD

Guideline-Based Recommendations

Diagnosis

• Utilize transcriptomic approaches to identify biomarkers associated with DMD

Management

• Consider corticosteroids such as prednisolone and deflazacort for palliative care

Monitoring & Follow-up

• Assess ECM activation scores and immune cell profiles in DMD patients

Risks

• Long-term efficacy and safety of corticosteroids remain uncertain

Patient & Prescribing Data

Individuals diagnosed with Duchenne Muscular Dystrophy

Current treatments are palliative; novel biomarkers and therapeutic targets are needed

Clinical Best Practices

• Integrate transcriptomic data for comprehensive analysis of DMD
• Monitor inflammatory pathways and immune cell infiltration in DMD progression
• Evaluate ECM remodeling as a factor in DMD management

Related Resources & Content

• Duchenne Muscular Dystrophy Overview
• Transcriptomic Approaches in DMD Research